Syncom Formulations Board Approves Q1 FY27 Results, Dividend, and Key Management Changes
Syncom Formulations' Board approved Q1 FY27 unaudited results and recommended a final dividend of ₹0.10 per share. Key management changes include resignations of MD, Whole-time Director, and CFO, and appointments of new MD, Whole-time Director, and CFO. The 38th AGM is scheduled for September 30, 2026.
The financial results and dividend are material. The management changes, including new appointments, could impact future strategy and operations, warranting a medium impact.
The approval of financial results and recommendation of a dividend are positive indicators. While there are significant management changes, the appointments suggest a planned transition.
Syncom Formulations (India) Limited announced the outcome of its Board Meeting held on August 11, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report from the auditors.
The Board also approved the Board's Report and Notice for the 38th Annual General Meeting (AGM) scheduled for September 30, 2026, to be conducted via Video Conferencing/Other Audio-Visual Means. The finalization of Book Closure and the Cut-off Date for remote e-voting for the AGM were also approved.
Key personnel changes were noted, including the resignation of Shri Kedarmal Shankarlal Bankda as Whole-time Director, Shri Vijay Shankarlal Bankda as Managing Director, and Shri Rahul Vijay Bankda as Chief Financial Officer, all effective from the close of business hours on August 11, 2026.
Further, the Board approved the appointment of Mrs. Rinki Ankit Bankda as Additional Director and Whole Time Director, and Shri Rahul Vijay Bankda as Additional Director and Managing Director, both effective August 12, 2026, subject to member approval. Shri Ankur Vijay Bankda was appointed as the new Chief Financial Officer, also effective August 12, 2026.
Additionally, the Board recommended a final dividend of ₹0.10 per equity share (10%) for the financial year ended March 31, 2026, subject to shareholder approval at the AGM. The record date for this dividend has been set as September 23, 2026.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.